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ABSTRACT
Mortality from acute variceal bleeding (AVB) has
improved markedly over the last 2–3 decades
due to increased specialisation and
standardisation of medical and endoscopic
practice culminating in the production of
consensus guidance based on expert opinion.
Nonetheless, despite greater exposure, training
and endoscopic practices, 30-day mortality still
remains high at around 30%. This is a reflection
of the high morbidity with liver disease, and
limited endoscopic experience and/or endoscopic
techniques used by the majority of general
endoscopists. Clinical necessity defines our drive
for further endoscopic innovation to improve
‘best practice’ and, therefore, clinical outcomes
accordingly. Sclerotherpy, variceal band ligation
and/or rescue balloon tamponade have been
entrenched in most treatment algorithms over
the decades. However, in recent years and albeit
limited to specialised liver centres, cyanoacrylate
glue injection therapy (for oesophageal and
gastric varices), and the placement of a self-
expanding metallic stent for oesophageal varices
have begun to offer improved endoscopic care in
experienced hands. Yet even in specialised
centres, their application is sporadic and operator
dependent. Here, we discuss the evidence of
these newer endoscopic approaches, and hope
to propose their inclusion in endoscopic therapy
algorithms for ‘best practice’ management of
AVB in all appropriately supported endoscopy
units.
BACKGROUND
Around 30–60% of patients with cirrhosis-
related portal hypertension (PHT) develop
varices as a physiological compensatory
mechanism to limit portal venous pressure.
Of the 10% of cirrhotics who develop
varices each year, 10% per year actually
bleed. Collectively, acute variceal bleeding
(AVB), ‘bleeding in the presence of varices
without another identifiable cause’, occurs
in around 30%,1 and accounts for 70–
80%2 of all upper gastrointestinal bleeding
episodes in patients with PHT. Due to
improved medical, endoscopic and inter-
ventional management, mortality from
AVB has fallen from 50% to around 30%
over the past 30 years, but this is still high,
and the abolition of AVB remains a clear
therapeutic goal.
The mainstay of therapy for AVB in
centres with the necessary facilities
involves fluid resuscitation, prophylactic
antibiotics,3 and vasoactive drugs (eg,
Terlipressin) combined with endoscopic
intervention. Traditional sclerosants such
as ethanolamine have been superseded
due to high variation in successful AVB
arrest (26–100%) and rebleeding rates
(60–90%) due to differential endoscopic
skill (eg, sclerosant volume injected) and
25% complication rate.4 Nowadays, vari-
ceal band ligation (VBL) has become the
mainstay of endoscopic therapy (grade
1A evidence) and the backbone of UK
guidance on the endoscopic management
of variceal bleeding.5 In patients with
Childs-Pugh score (CPS) A or B cirrhosis
such measures correlate with a 90%
30-day survival, but equally, therefore,
10% of CPS A-B patients still die despite
intervention. This figure is inherently
higher in those patients with poor
end-organ reserve (CPS C) especially
where there has been a failure to gain
primary bleeding arrest and/or they
rebleed; such that further supportive and
endoscopic intervention becomes increas-
ingly challenging.
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As a means of bridging the patient to either more
definitive therapy, rescue therapies like balloon tam-
ponade (BT) may be necessary, though frequently per-
formed in acutely unstable circumstances by those
with limited experience, resulting in greater potential
for complication. A failure of primary AVB arrest,
rebleeding and/or complications from prior interven-
tion (eg, VBL, BT etc.) not uncommonly requires
repeat endoscopic intervention by an experienced
endoscopist, and/or insertion of a transjugular intrahe-
patic portosystemic shunt (TIPS). Aside from BT, most
of these therapies are not universally available, and
are chiefly limited to larger specialised centres and/or
in some circumstances contraindicated if not consid-
ered futile by many non-specialists given the tradition-
ally pessimistic approach of non-specialists to patients
with chronic liver disease.
Regardless, endoscopic therapy remains central to
the management of oesophageal and gastric AVB, but
different anatomical considerations dictate a varied
response to interventions for oesophageal and gastric
varices. Recently, in primarily specialist centres, two
new endoscopic modalities have become increasingly
prominent in AVB management, (1) cyanoacrylate
(glue) injection therapy and (2) self-expandable metal
stent (SEMS). This review focuses on these two ther-
apies and proposes their wider inclusion in guidance
on endoscopic variceal management within endoscopy
units including non-specialist centres which have
appropriate expertise and support.
VARICEAL ANATOMY
To best understand differing therapeutic endoscopic
considerations for the management of AVB, one must
understand the anatomical differences in variceal for-
mation, as although gastric varices bleed less fre-
quently, they are often associated with a more severe
bleed that may be more difficult to manage.
Oesophageal varices
Oesophageal varices normally result from PHT as a
complication of cirrhosis, or prehepatic or posthepatic
vascular occlusion. Actually, the majority of blood
from the oesophagus is not involved in variceal for-
mation as the oesophageal veins drain into the azygos
vein and then the superior vena cava. However, the
remaining blood drains from the oesophagus via the
superficial veins lining the oesophageal mucosa,
which then flows into the left gastric vein (coronary
vein) and, in turn, drains directly into the portal vein.
With progressive PHT these superficial veins (nor-
mally only ∼1 mm in diameter) become distended to
form varices (∼1–2 cm in diameter). In health only a
small amount of blood flows from the oesophagus
into the left gastric vein; these are the channels that
enlarge in portal hypertension (HTN) and blood flow
is reversed.
Normal portal pressure is approximately 9 mm Hg
compared to an inferior vena cava pressure of
2–6 mm Hg, creating a pressure gradient of
3–7 mm Hg. If the portal pressure rises above
12 mm Hg, this gradient rises to 7–10 mm Hg.
A gradient ≥5 mm Hg is considered PHTand at gradi-
ents ≥10 mm Hg, hepatic portal blood is redirected
from the liver to form collateral circulation at areas
with lower venous pressures (eg, oesophagus, abdom-
inal wall, stomach and rectum). As pressures rise,
these collateral vessels become increasingly distended
and thin-walled, appearing as varicosities that may
easily bleed, as also poorly supported by surrounding
structures.
Gastric varices
Gastroesophageal varices are an extension of oesopha-
geal varices and are categorised (figure 1) by their
relationship to oesophageal varices and location in the
stomach. Type-1 (GOV1) varices extend along the
lesser curvature and are considered extensions of
oesophageal varices and therefore similarly managed.
Type-2 (GOV2) gastric varices extend along the
fundus and tend to be longer and more tortuous.
Isolated gastric varices (IGV) occur in the absence of
Figure 1 (A–D): Gastric variceal anatomy. Classification of
different types of gastric varices based on their anatomical
position in the stomach are depicted in figure (A). GEV1:
gastro-oesophageal varices type 1, (B). GEV2: gastro-oesophageal
varices type 2, (C). IGV1: isolated gastric varices type
1. (D) IGV2: isolated gastric varices type 2.
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oesophageal varices and are also classified into two
types (figure 1). Type 1 (IGV1) are located in the
fundus and tend to be tortuous and complex, and
type 2 (IVG2) are located in the body, antrum or
pylorus. The presence of isolated IGV1 fundal varices
requires that one excludes the presence of splenic vein
thrombosis which is often the trigger of IGV.
ENDOSCOPIC MANAGEMENT
Traditionally, oesophageal varices are treated with
VBL and/or sclerotherapy. VBL has proven more bene-
ficial especially versus the traditional (and now out-
dated) sclerosant agents such as alcohol and
ethanolamine.6 However, newer agents like ‘cyano-
acrylate’ glue injection therapy have quickly shown
benefit in the management of oesophageal and gastric
varices
ENDOSCOPIC MANAGEMENT OF OESOPHAGEAL
VARICES
To date, there has been limited data assessing the role
of glue therapy in the treatment of oesophageal vari-
ceal bleeding (OVB). The largest series and most con-
vincing evidence comes from a prospective study of
133 consecutive cirrhotic AVB patients treated by
intravariceal glue injection.7 Immediate haemostasis
was achieved in 94.2% (n=49/52) of those with active
bleeding. Early recurrent bleeding occurred in 5.2%
(n=7/49) with no major procedure-related complica-
tions reported, but overall bleeding-related mortality
was 8.2% and, not unsurprisingly, higher (15.4%) in
those with active bleeding at endoscopy compared to
(3.7%) non-active bleeders. However, of those surviv-
ing the first bleeding episode, 84% (n=112/133) sub-
sequently underwent oesophageal band ligation
(OBL). Therefore, one can only conclude that
although not first-line, emergency glue injection is
generally safe and effective for the treatment of acute
OVB and does not hinder subsequent OBL. However,
this study did not mention the degree of liver cirrhosis
and other organ dysfunction which would generally
predict poor outcomes in those patients.
ENDOSCOPIC MANAGEMENT OF GASTRIC
VARICES
Gastric variceal bleeding (GVB) accounts for 10–15%
of all variceal bleeds (figure 4). Following general sup-
portive measures (eg, resuscitation, terlipressin and
antibiotics), the endoscopic management of acute
GVB is difficult in the light of active bleeding or
rebleeding as often technically challenging given
gastric variceal anatomical and physiological consid-
erations. Although successful haemostasis and obliter-
ation of gastric varices are reported with VBL and
certain sclerosing agents (eg, absolute alcohol), results
are variable if not typically poor.8 Where primary
haemostasis was not achieved and/or later re-bled, BT
is necessary to bridge the patient to more definitive
intervention such as TIPS, surgical shunt and, if
appropriate, transplantation. If locally available, and
in appropriate patients (eg, absence of significant HE
episode) early TIPS placement is known to arrest AVB
and reduce rebleeding rates from oesophageal and
gastric varices,9 by reducing portal pressure as AVB is
unlikely if hepatic vein pressure gradient (HVPG) is
≤12 mm Hg,10 Even with successful TIPS (reducing
HVPG ≤12 mm Hg), gastric varices have a tendency
to bleed despite low portal pressures. However, over
recent years, there has been the increasing and suc-
cessful application of cyanoacrylate glue therapy for
refractory oesophageal and gastric AVB leading to
immediate haemostasis and variceal obliteration.
Based on published evidence, glue is more effective
than band ligation for gastric varices.
CYANOACRYLATE INJECTION THERAPY
Administration
The tissue glue, N-butyl-2-cyanoacrylate, is a watery
solution that polymerises and hardens within 20 s in a
physiological milieu and instantaneously on contact
with blood. Rapid solidification of glue makes endo-
scopic application technically difficult, necessitating
its dilution with the oily contrast agent Lipiodol Ultra
Fluid (Therapex, Canada) to improve administration
(figure 2). A 50:50 mixture of cyanoacrylate and
Lipiodol (in preference to saline) is arguably the best
dilution protocol for injection as allows for controlled
application and limited risk of embolisation. A thera-
peutic endoscope with a 3.7 mm working channel is
preferred to allow for accurate control of the injector
catheter (a standard gastroscope with a 3.2 mm
channel often does not allow the injection catheter to
pass when the gastroscope is retroflexed in the
stomach). There had been no consensus to whether
glue therapy should be in the treatment algorithm for
either oesophageal or gastric AVB, and what recent
studies have been reported are relatively small, non-
randomised and have not been compared with endo-
scopic variceal ligation (EVL), the current standard of
care.11
Evidence for cyanoacrylate in GVB
There has been a number of small non-randomised
studies, mainly case series, of GVB treated with cyano-
acrylate glue therapy. Collectively, in over 1000
reported cases, active variceal bleeding was arrested in
93–100%, with rates of recurrent bleeding around
10%.
In a case series of 34 (n=34) patients receiving
primary glue therapy for AVB, 93.8% achieved imme-
diate haemostasis with variceal obliteration in 84%.
Only 11.8% (n=4) re-bled within 48 h, and a super-
ior mesenteric vein thrombosis complicated one case.
There was a treatment failure-related mortality of only
2.1% (n=1), with 82.4% (n=28) of patients alive at
the end of follow-up.
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Similarly, Jaber Al-Ali et al12 reported 95% primary
haemostasis with cyanoacrylate glue injection in 37
(n=37) cases of GVB. Early or late rebleeding
occurred in only 8% (n=3) and 28% (n=10), respect-
ively, and all ‘non-life-threatening’. Over 14 months
follow-up (achieved in 79%), all-cause mortality rate
was 28.6% (n=11), with no significant cyanoacrylate
injection-related complications.
Rajoriya et al,13 reported 100% primary haemosta-
sis with cyanoacrylate glue injection in 31 (n=31)
GVB patients with more advanced disease (CPS B/C)
and active bleeding (58% periprocedure). Over the
35-month mean follow-up (57 months for survivors),
rebleeding rate was 10% at 1 year and 16% in total.
Thirteen per cent required subsequent TIPS, with 1
and 2-year mortality of 23% and 35%, respectively.
Complications with cyanoacrylate administration
Endoscopic glue-injection therapy is not without risk
as is associated with distal systemic thromboembolic
events, such as pulmonary embolism (pulmonary
vessels), acute kidney injury,14 (renal vessels) as well as
Figure 2 (A–F): Temporal endoscopic views of glue-injection therapy for an acute VGB and subsequent treatment response.
Endoscopic images from serial endoscopies (over 4 weeks) for a patient treated with intravariceal glue-injection therapy for a massive
acute variceal bleeding (AVB) are represented in (A). Gastroscopy within 24 h of presentation (when patient stabilised following
standard medical care and necessary resuscitation) showing an ongoing active bleeding from a GOV1 gastric varix. A
Sengstaken-Blakemore tube (BT) was inserted immediately, as the endoscopist had little experience with glue therapy. (B) Appearance
of gastric varices 8 h post-BT and prokinetic to aid endoscopic views. (C) Injecting varices with glue (histoacryl and lipiodol-mixed
solution). (D) Early extravasation of glue (histoacryl and lipiodol solution) 48–72 h post-glue injection therapy. (E) Well formed
histoacryl and lipiodol cast, 2 weeks postinjecting therapy. (F) Complete eradication of gastric varices with histoacryl and lipiodol
therapy.
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obliteration of splenic or portal vein; the latter poten-
tially precluding liver transplantation. There have
been other reported complications, such as gastric
ulcer formation (0.1%), major GVB (0.1%), and mes-
enteric haematoma, haemoperitoneum, bacterial peri-
tonitis (0.1%), and reports of recurrent and
prolonged bacterial sepsis due to retained embolised
glue casts.14 Retained material may act as an infective
foci14 15; with subsequent cast breakdown intermit-
tently releasing colonised microbes into the circula-
tion. Therefore, embolised glue may persist beyond
24 weeks and should be considered if recurrent infec-
tion develops, which may necessitate protracted
courses of antibiotics. This reiterates the need for
caution with glue. To potentially reduce such risks
endosonographic-endoscopic ultrasound (EUS) or
fluoroscopic-guided administration is advocated in
certain countries, but as yet is not general practice in
the UK. Direct ultrasound-guided endoscopy should
offer safer gastric variceal puncture, partly due to a
more stable position in the lower oesophagus in com-
parison with gastric retroflexion. Such targeted inter-
vention should reduce glue volume, especially with
synthetic fibre coil placement, and reduce the risk of
systemic complications (eg, PE). EUS also allows for
surveillance to predict the risk of further bleed.
ENDOSCOPIC ULTRASOUND-GUIDED
THERAPY (EUS)
EUS began in 1980 and over the years has become an
integral part of diagnostic and interventional endos-
copy. EUS-guided therapy offers a potentially safer
approach to the management of GVB given reports of
glue embolisation and potential fatality complicating
endoscopic glue therapy. EUS-guided therapeutic
endoscopy is considered by some experts to allow for
more targeted glue and/or coil deployment in bleeding
or non-bleeding gatric fundal varix (GFV) and aid
variceal obliteration.16 In 2013, Romero-Castro et al
published a series of 30 consecutive patients with IGV
who received either EUS-guided glue injection (n=11/
30) or endoscopic coil application (ECA) (n=19/30)
with up to 6 months postprocedure review.17 The GV
obliteration rate with EUS-guided glue injection was
94.7% vs 90.9% for EUS-guided ECA, with adverse
events occurring in 40% (57.9% of glued patients,
but only 9.1% post-ECA (p<0.01)). Interestingly,
81% of those glued showed CT evidence of embolism
(sites not reported) though 80% of these were asymp-
tomatic. Although 20% (n=6/30) of study patients
died over the study follow-up period, all were unre-
lated to endoscopy or AVB.17 EUS-guided glue injec-
tion and ECA, therefore, showed excellent and
comparable clinical benefit though it could be argued
that ECA may be the safer modality. In AVB patients,
Binmoeller et al16 had previously assessed if combin-
ing ECA (incorporating attached synthetic fibres) to
EUS-guided glue injection would reduce the risk of
glue embolisation (presumably by limiting total
injected glue volume). Patients with acute (n=2) or
recent stigmata (n=14) of GVB were studied and
followed-up over a 2-year period. Haemostasis was
achieved in 100%, with variceal obliteration observed
after a single treatment session in 96%. In the 16% of
those who re-bled, none was due to GVB.
Importantly, there were no endoscopy-related compli-
cations or evidence of glue embolisation.
SEMS FOR OVB
Placement of a fully covered SEMS is a promising thera-
peutic technique to control cases of refractory oesopha-
geal bleeding as an alternative to BT (figure 3). SEMS
further allow for an immediate return to enteral feeding
and can be left in place for 1–2 weeks to allow for
improvement in liver function and a bridge to the insti-
tution of more definitive treatment (eg, TIPS or
transplantation).
Figure 3 (A and B): Endoscopic views of a successfully deployed self-expandable metal stent for AVB.
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The studies in support of SEMS have mainly used
the specifically designed SX-ELLA Danis stent
(ELLA-CS, Hradec Kralove, Czech Republic) a remov-
able, fully covered, polyurethane membrane-covered
self-expanding metal stent (SX-ELLA stent Danis,
135 mm×25 mm ELLA-CS, Hradec Kralove, Czech
Republic). The Ella Danis stent can be deployed
without radiological or endoscopic guidance. The
stent has atraumatic edges and radiopaque markers at
both ends and midpoint of the stent to easily assess its
position by plain radiography. The stent can be
removed endoscopically using a special extractor kit
(PEX-ELLA or Extractor for SX-ELLA stent Danis)
without causing soft tissue damage.18
EVIDENCE FOR SEMS IN AVB
The initial pilot study by Hubmann et al19 was pub-
lished in 2006, assessing SEMS as an alternative to BT
in 20-patients (18 men, two women; mean age 52
years, Childs B/C) with refractory variceal bleeding
despite pharmacological and endoscopic therapy.
Three different types of stents were used; two
(n–2/20) patients received standard oesophageal Choo
stentsTM (diameter 18 mm, length 140 mm;
NES-18-080-070, M.I.Tech, Korea), three (n=3/20) a
ELLA-Boubela-Danis stent (diameter 20 mm, length
95 mm; ELLA-CS, Hardec Kralove, Czech Republic)
and 15 (n=15/20) the specifically designed
ELLA-Danis stent (diameter 25 mm, length 135 mm)
that has a special introducer for placement without
radiological or even endoscopic control. In all patients,
upper endoscopy and chest X-ray were performed
within 12 h to confirm correct stent position. In 19
(n=19/20) patients, primary haemostasis (with no later
rebleeding episodes), but in that one (n=1/20) case,
ongoing bleeding was attributable to GVB that resulted
in the need for total gastrectomy and open azygoportal
disconnection to control ongoing bleeding. Stent
migration was observed in five (n=5/20) cases, but
only two (n=2/15) patients with an ELLA-Danis stent.
Reflective of the severity of bleed and associated
liver decompensation with multiple organ dysfunction,
in the absence of continued bleeding episodes, two
(n=2/20) patients died of multiple organ failure, at day
3 and day 5 day post-SEMS insertion, respectively.
Four (n=4/18) patients required scheduled VBL,
however, the remaining 14 (14/20) patients were
bridged to more definitive treatment patients including
TIPS (n=5/18), laparoscopic azygoportal disconnec-
tion (n=5/18), radiologically guided coiling (n=1/18)
and, ultimately, liver transplantation (n=3/18).18 In
2008, Zehetner et al20 reported their findings on 39
(n=39) cases of SEMS insertion for refractory
oesophageal AVB unresponsive to conventional
methods. Thirty-four (n=34/39) of these patients
received a SX-ELLA Danis stent (deployed without
fluoroscopy) leading to primary bleeding arrest in all
(n=34/39). No bleeding recurrence or stent-related
complications occurred during or after stent implant-
ation, nine (n=9/39) patients died of hepatic failure
within 30 days postprocedure. The median duration of
stent implantation was 5 days (range 1–14 days) with
all stents removed by endoscopy using the accompany-
ing extractor device.
We have previously published our transplant centre
experience of 10 cases of refractory variceal haemor-
rhage treated with a SX-ELLa Danis SEMS.21 A SEMS
was successfully implanted in nine (n=9/10) patients,
with only one (n=1/10) insertion failure due to inad-
equate delivery balloon inflation. Primary haemostasis
was achieved with SEMS insertion in six (n=6/9)
patients, with continued bleeding reported in three
(n=3/10) cases, of which two were due to gastric
AVB. Six (n=6/10) patients survived the acute bleed-
ing episode and had stents removed endoscopically at
a median of 9 days after insertion. Overall survival at
42 days was 50%. Only in one (n=1/10) case was the
process of SEMS insertion complicated (by a minor
oesophageal ulcer) related to stent placement in what
was otherwise a straightforward, quick and safe pro-
cedure with effective control of bleeding without the
necessity for fluoroscopic control. This study also
indicated that SX-Ella DANIS SEMS insertion offers
an alternative to other methods of salvage such as BT
and TIPS. Whether SEMS insertion is a substitute for
primary EVL, for oesophageal, AVB, or BT, is the
principle question of a current prospective rando-
mised controlled trial from the same authors, with the
results expected in 2014.
Dechene et al,18 published their experience of using
SEMS for refractory AVB (despite standard pharmaco-
logical therapy) in eight (n=8) cirrhotic patients with
stenting resulted in immediate haemostasis and no
reported rebleeding episodes in all cases. Three (n=3/5)
patients experienced recurrence of variceal bleeding
within 9 days of stent removal. One (n=1/8) patient
with a high risk of rebleeding was bridged to TIPS;
though post-TIPS rebleeding required TIPS dilatation. A
further (n=1/8) patient was bridged to orthotopic liver
transplantation. Furthermore, SEMS were removed
without complication after a median of 11 days. Mishin
et al,22 reported the case of a 49-year-old man present-
ing with AVB on a background of (Childs-C)
viral-induced cirrhosis. Primary haemostasis was initially
achieved by VBL, but had a late massive rebleed from
banding ulceration (on day 8). Placement of a SX-ELLA
Danis stent led to complete haemostasis, with its
removal at day-8 postinsertion without rebleeding or
other complication. This case serves to highlight the
benefit of SEMS as rescue therapy for variceal rebleed-
ing (table 1).
BALLOON-OCCLUDED RETROGRADE
TRANSVENOUS OBLITERATION
In the small group of patients with AVB advanced
decompensated cirrhosis poorly amenable to TIPS
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(contraindicated, technically/clinically challenging),
and/or where other interventions have failed,
balloon-occluded retrograde transvenous obliteration
(BRTO) is a consideration. It is also a therapeutic
option for ectopic varices.23 BRTO is available in only
a very few specialist liver centres with good interven-
tional radiology as essentially involves the difficult
process of achieving transvenous access to the porto-
systemic circulation by a gastrorenal shunt commonly
via venous puncture of the left renal vein through a
transjugular or transfemoral approach. Moreover,
sclerotherapy (eg, Ethanolamine oleate and sodium
tetradecyl sulfate (STS) foam) is an important adjunct
to mechanical balloon-occlusion to improve variceal
obliteration. In a case series of 22 decompensated cir-
rhotics with AVB, BRTO achieved successful variceal
obliteration in 91%, with complications occurring in
only 14% patients and no reported cases of recurrent
variceal bleeding (mean clinical follow-up period of
130 days (range 1–510).24
FUTURE THERAPIES
Non-endoscopic
Novel non-endoscopic approaches are also likely to
add to therapeutic options. The most likely of these is
Tranexamic acid, a plasmin inhibitor that maintains
clot stability by limiting fibrinolysis, is currently being
trialled in the Haemorrhage ALleviation with
Tranexamic acid-InTestinal system (HALT-IT) study, a
large, international, randomised, double-blind,
placebo-controlled trial, directly evaluating its role in
acute upper GI bleeding. However, a degree of
caution is necessary, as previous interventions, such as
Factor-VIIa, despite early promise failed in phase 4
studies to show a significant impact on AVB (failure to
control acute bleeding, prevent 5-day rebleeding and/
or death, and 42-day mortality) compared with
placebo.25
Endoscopic therapies
There are little new endoscopic therapeutic
approaches which show promise, but control of vari-
ceal bleeding with endoscopically applied haemostatic
powder (Hemospray) looks interesting. This agent is
an inorganic haemostatic powder that becomes cohe-
sive and adhesive to form a stable mechanical barrier
over the bleeding site; it is also reported to increase
local clotting factors and activate the intrinsic clotting
cascade. However, supportive data is currently limited
to only a few case series predominantly in non-
variceal bleeding,26one case series,27 and isolated case
reports in GVB28 29; usually following failure of other
endoscopic methods. Therefore, its use will need to
stand up to more critical review with following more
comprehensive randomised clinical trials.
Injection of Thrombin has been around for some
time, but data had been limited. Recently however, a
large prospective study suggests that Thrombin would
be a good option for units where glue-injection is not
already an option.30
CONCLUSIONS
In the management of AVB, SEMS has been rarely
used outside of a few selected liver units, despite
published non-randomised trial data suggesting
improved outcomes versus standard medical therapy
and OBL with ongoing/rebleeding variceal episodes.
We therefore propose that SEMS should be the pre-
ferred intervention for refractory OVB after failed
VBL or Sengstaken-Blakemoore tube (SBT)
(figure 4). Moreover, randomised control trials are
underway to establish whether this novel modality
would be of benefit in the primary management in
preference to EVL in current treatment algorithms.
Although the relatively high unit cost (£2000) per
SEMS may initially be considered a limiting factor
for its wider use, this should be offset against the
Table 1 Evidence of SEMS in AVB.
Year n=patients
SEMS
successfully
deployed (%)
Immediate
haemostasis (%)
Rebleeding
(%)
SEMS
migration
(%)
Median (range)
days to stent
removal
Mortality
follow-up
period
Hubmann
et al
2006 15 100 100 0 13 5 (1–14) 20% 60 days
Zehetner
et al
2008 34 100 100 0 18 5* (1–14) 29% 60 days
Wright
et al
2010 10 90 70 14 NR 9 (6–14) 50% 42 days
Dechene
et al
2012 8 100 100 38 0 11 (7–14) 75% 60
Holster
et al
2013 5 100 100 20 20 11 (6–214) 40% 180 days
Zakaria
et al
2013 16 94 88 0 38 NR (2–4) 25% NR
*Represents mean (not median).
NR, not reported; SEMS, self-expandable metallic stents.
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significant cost savings due to less rebleeding epi-
sodes and sequelae.
Additionally, there is good and growing evidence
for endoscopic variceal obliteration using
N-butyl-2-cyanoacrylate as a first-line endoscopic
therapy for AVB, especially for GV bleeds where treat-
ment options remain limited.
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